A Decentralized Clinical Study Evaluating the Effectiveness of Two Different Doses of MyCondro™ on Physical Mobility and Joint Health

Conditions

• Joint Health

Eligibility Criteria

Sex

ALL

Age

45 Years - N/A

Healthy Volunteers

Accepted

Interventions

• MyCondro 300mg — DIETARY_SUPPLEMENT
  This is a non-animal Chondroitin sulfate formulation.
• MyCondro 600mg — DIETARY_SUPPLEMENT
  This is a non-animal Chondroitin sulfate formulation.

Study Details

This study evaluates the effect of two different doses of a consumer-grade product, MyCondro™, on individuals experiencing mobility issues related to knee osteoarthritis. The primary goal is to measure improvements in overall joint health and mobility by tracking changes in participants' total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) scores from the beginning to the end of the trial. Additionally, the study aims to assess secondary outcomes, including the product's impact on pain, stiffness, knee function, patient-reported improvement, inflammatory blood markers (CRP), and daily physical activity.

Key Dates

Start date

Mar 31, 2026

Status verified

Mar 2026

Primary completion

Oct 5, 2026

Completion

Nov 2, 2026

Study Design

Enrollment

240 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Arms

• Experimental: 300 mg
  Participants in this arm will receive a 300 mg daily dose of the supplement, administered as two capsules every morning after breakfast for a 12-week period
• Experimental: 600 mg
  Participants in this arm will receive a 600 mg daily dose of the supplement, administered as two capsules every morning after breakfast for a 12-week period

Primary Outcome Measure

MyCondro's effectiveness [ Time Frame: 12 weeks ]

Central Contacts

• Victoria Oyedokun, PhD
  +4915163496903
  [email protected]
• Yann Fardini, PhD
  [email protected]

Locations (1)

Find similar trials in Los Angeles, CA